BioCentury | Nov 17, 2017
Clinical News

Biscayne reports Phase Ib data for epilepsy candidate BIS-001ER

...focal seizures Endpoint: Pharmacokinetics; safety Status: Phase Ib data Milestone: Start Phase IIa (early 2018) Allison Johnson BIS-001...
BioCentury | Feb 3, 2017
Company News

Biscayne Pharmaceuticals deal

...Pharmaceuticals spun out CNS company Biscayne Neurotherapeutics Inc. (Miami, Fla.). The newco's sole asset is BIS-001... development to treat refractory forms of epilepsy, including partial complex seizures and Dravet syndrome. BIS-001...
...trial mid-year using its new extended-release formulation. Biscayne Pharmaceuticals Inc. , Miami, Fla. Business: Neurology Alex Himes BIS-001 Biscayne...
BioCentury | Nov 2, 2015
Company News

Biscayne Pharmaceuticals, Insero Health deal

...June 30. Biscayne is developing growth hormone-releasing hormone (GHRH) receptor analogs. Biscayne’s lead compound is BIS-001...
Items per page:
1 - 3 of 3